openPR Logo
Press release

Ovarian Cancer Industry to Grow at a CAGR of 11.40% during 2022-2027 -IMARC Group

11-23-2022 04:59 PM CET | Health & Medicine

Press release from: IMARC Group

Ovarian Cancer Industry to Grow at a CAGR of 11.40% during

IMARC Group has recently released a new research study "Ovarian Cancer Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027", offers a detailed analysis of the market drivers, segmentation, growth opportunities, trends, and competitive landscape to understand the current and future market scenarios.

What are the growth prospects of the Ovarian Cancer Industry?

The global ovarian cancer market size reached US$ 1.68 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 3.34 Billion by 2027, exhibiting a growth rate (CAGR) of 11.40% during 2022-2027.

Impact of COVID-19:

We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.

Request For Sample Report https://www.imarcgroup.com/ovarian-cancer-market/requestsample

What is a Ovarian Cancer Market ?

Ovarian cancer represents a malignant tumor wherein irregular cells in the begin to develop and multiply uncontrollably from the outer tissue lining or fallopian tubes, owing to mutagenic changes in the deoxyribonucleic acid (DNA). It can be treated through various diagnoses and drugs, such as antineoplastic, antirheumatics, mitotic, PARP, and VEGF/VEGFR inhibitors.

In addition, ovarian cancer treatment involves chemotherapy, surgery, hormone, radiation, and targeted therapies that aid in killing the cancer cells to provide relief from signs and systems. These therapeutics are conducted by medical practitioners across hospitals and specialty centers after determining several factors, such as the spread of the tumor, the general health of an individual, and the size and type of ovarian cancer.

What are the major market drivers in the Ovarian Cancer Market ?

The escalating prevalence of epithelial, stromal, and germ cell cancer, especially among the female geriatric population, on account of the genetic mutation of BRCA2 or breast cancer gene 1 (BRCA1), is primarily driving the ovarian cancer market. Besides this, the elevating requirement for effective therapeutic drugs, including bevacizumab (Avastin) and pazopanib (Votrient), is further augmenting the market growth.

Moreover, the launch of several policies by the government bodies to sensitize consumers toward the treatments, symptoms, and benefits of early ovarian cancer diagnosis is also catalyzing the global market. Apart from this, the growing popularity of combination therapies in the healthcare sector to increase medicine efficacy and prevent drug resistance is acting as another significant growth-inducing factor.

Additionally, the ongoing patent expiration of branded medications has prompted pharmaceutical companies to launch novel recombinant drugs, which is also stimulating the market growth. Furthermore, the strategic collaborations among the leading players and the extensive research and development (R&D) activities to produce efficient therapeutic interventions are anticipated to propel the ovarian cancer market over the forecasted period.

Ask Analyst for Customization and Browse full report with TOC & List of Figure: https://www.imarcgroup.com/ovarian-cancer-market

Report Segmentation:

The report has been segmented the market into following categories:

Breakup by Type:
o Epithelial Ovarian Cancer
o Germ Cell Ovarian Cancer
o Stromal Cell Ovarian Cancer

Breakup by Treatment Type:
o Immunotherapy
o Chemotherapy
o Targeted Therapy
o Surgery
o Others

Breakup by End User:
o Hospitals
o Homecare
o Speciality Centre
o Others

By Geography:
• North America (United States, Canada)
• Europe (Germany, France, United Kingdom,
Italy, Spain, Others)
• Asia Pacific (China, Japan, India, Australia,
Indonesia, Korea, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa (United Arab Emirates, Saudi Arabia, Qatar, Iraq, Other)

List of Major Key Players:

The major players in the market are
AbbVie Inc.
Amneal Pharmaceuticals Inc.
AstraZeneca plc, Eli Lilly and Company
F. Hoffmann-La Roche AG, GSK plc
Hikma Pharmaceuticals PLC
Lupin Limited, Pfizer Inc.
and Teva Pharmaceutical Industries Ltd.

Key highlights of the report:

• Market Performance (2016-2021)
• Market Outlook (2022- 2027)
• Porter's Five Forces Analysis
• Market Drivers and Success Factors
• SWOT Analysis
• Value Chain
• Comprehensive Mapping of the Competitive Landscape

If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.

Browse Other Industry Research Report-

Intravenous (IV) Ibuprofen Market Size 2022-2027-https://www.imarcgroup.com/intravenous-ibuprofen-market

Motor Insurance Market Report 2022-2027-https://www.imarcgroup.com/motor-insurance-market

Solar Farm Market Forecast 2022-2027-https://www.imarcgroup.com/solar-farm-market

Prestressed Concrete (PC) Wire and Strand Market Size 2022-2027- https://www.imarcgroup.com/prestressed-concrete-wire-strand-market

HVDC Transmission Systems Market size 2022-2027-https://www.imarcgroup.com/motor-insurance-market

Endoscopic Retrograde Cholangiopancreatography Market 2022-2027-https://www.imarcgroup.com/endoscopic-retrograde-cholangiopancreatography-market

FMCG Logistics Market Forecast 2022-2027-https://www.imarcgroup.com/fmcg-logistics-market

Nucleotides Market 2022-2027-https://www.imarcgroup.com/nucleotides-market

Contact Us:

IMARC Services Private Limited.
30 N Gould St Ste R
Sheridan, WY 82801 USA - Wyoming
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC's information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company's expertise.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Ovarian Cancer Industry to Grow at a CAGR of 11.40% during 2022-2027 -IMARC Group here

News-ID: 2818930 • Views:

More Releases from IMARC Group

Global Cellulose Prices Q2 2025 - Trend, News & Insights
Global Cellulose Prices Q2 2025 - Trend, News & Insights
North America Cellulose Prices Movement Q2 Cellulose Prices in United States: In Q2 2025, US Cellulose Prices were pressured by reduced output at pulp mills due to maintenance and labor shortages. Timber harvesting delays from adverse weather constrained raw material supply. Steady demand from packaging and construction supported consumption, while rising fuel surcharges and logistics costs added to overall pricing challenges. Get the Real-Time Prices Analysis: https://www.imarcgroup.com/cellulose-pricing-report/requestsample APAC Cellulose Prices Movement Q2: Cellulose Prices in
E-Waste Manufacturing Plant Report 2025: Raw Materials Requirement, Setup Cost and Revenue
E-Waste Manufacturing Plant Report 2025: Raw Materials Requirement, Setup Cost a …
E-Waste refers to discarded electronic devices such as computers, smartphones, televisions, and household appliances that have reached the end of their life cycle. It contains both valuable materials like gold, copper, and rare earth elements, as well as hazardous substances such as lead, mercury, and cadmium, making proper recycling crucial for environmental safety and resource recovery. Setting up an e-waste recycling plant requires investment in land, machinery for dismantling and extraction,
Cement Bricks Manufacturing Plant Report 2025: Business Plan, and Setup Details
Cement Bricks Manufacturing Plant Report 2025: Business Plan, and Setup Details
Cement bricks are solid or hollow rectangular blocks made from a mixture of cement, sand, and aggregates, molded and cured for strength and durability. They are widely used in construction due to their uniform shape, load-bearing capacity, resistance to fire and weather, and cost-effectiveness compared to traditional clay bricks. Setting up a cement bricks manufacturing plant involves securing land, installing machinery like mixers and molding units, sourcing raw materials, and employing
Propyl Cyanoacetate Production Cost Report 2025: Detailed Guide on Plant Setup, CapEx/OpEx and Profitability
Propyl Cyanoacetate Production Cost Report 2025: Detailed Guide on Plant Setup, …
Setting up a propyl cyanoacetate production facility necessitates a detailed market analysis alongside granular insights into various operational aspects, including unit processes, raw material procurement, utility provisions, infrastructure setup, machinery and technology specifications, workforce planning, logistics, and financial considerations. IMARC Group's report titled "Propyl Cyanoacetate Production Cost Analysis Report 2025: Industry Trends, Plant Setup, Machinery, Raw Materials, Investment Opportunities, Cost and Revenue" offers a comprehensive guide for establishing a propyl cyanoacetate

All 5 Releases


More Releases for Ovarian

Ovarian Cancer Market Size, Future Trends
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- The global Ovarian Cancer Market is expected to record a CAGR of XX.X% from 2024 to 2031 In 2024, the market size is projected to reach a valuation of USD XX.X Billion. By 2031 the valuation is anticipated to reach USD XX.X Billion. The impact of manufacturers on the market is significant across various industries, influencing supply chains, consumer choices, and economic growth. Manufacturers are key players in
Polycystic Ovarian Syndrome Treatment Market Report
The findings reviewed by GME stated that the Global Polycystic Ovarian Syndrome Treatment Market will expand with a CAGR value of 5.2 percent from 2021 to 2026. The rising incidence of PCOS increased understanding among a group of patients, and the growing acceptance of standard treatment boosts the PCOS treatment industry growth over the projected timeframe. Furthermore, the research and development of PCOS are predicted to aid in market growth. Browse
Ovarian Cancer Drugs Market Report 2020-2030
Forecasts by Therapeutic Class (PARP, PD-L1, Angiogenesis Inhibitors) Plus Analysis of Leading Companies Download free sample pages: https://www.visiongain.com/report/ovarian-cancer-drugs-market-report-2020-2030/ Ovarian Cancer Drugs Market- our new study reveals trends, R&D progress, and predicted revenues Where the Ovarian Cancer Drugs is market heading? If you are involved in this industry you must read this newly updated report. Visiongain's report shows you the potential revenues streams to 2030, assessing data, trends, opportunities and business prospects there. Discover
How deadly is Ovarian Cancer?
Ovarian Drugs and Treatment Market describes its growth, size, share, Forecast and trends to 2025 Ovarian cancer is a cancer that forms in or on an ovary. It results in abnormal cells that have the ability to invade or spread to other parts of the body. The global Ovarian Cancer Treatment Drugs market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025,
Polycystic Ovarian Syndrome Treatment Market - Regional Analysis
The organic and inorganic strategies by the market players will boost the polycystic ovarian syndrome treatment market. For instance, in 2016, Millendo Therapeutics, Inc., a biopharmaceutical company, entered into an exclusive license agreement with AstraZeneca for the development and commercialization of phase II entered AZD4901, a candidate product for the treatment of polycystic ovarian syndrome. Moreover, in 2017, Astellas Pharma Inc. completed its acquisition of Ogeda SA (formerly Euroscreen S.A.).
Ovarian Cancer - Heat Map and Analysis
ReportsWorldwide has announced the addition of a new report title Ovarian Cancer - Heat Map and Analysis to its growing collection of premium market research reports. Ovarian Cancer (OC) is the fifth most common malignancy diagnosed in women, and the most common gynecological cancer, with an estimated 225,000 new cases diagnosed globally in 2008. Rates are particularly high in developed countries, and especially in Northern Europe. However, substantial improvements in